Corvus Pharmaceuticals Reaches Analyst Target Price
September 20, 2021 at 10:29 AM EDT
In recent trading, shares of Corvus Pharmaceuticals Inc (CRVS) have crossed above the average analyst 12-month target price of $5.12, changing hands for $5.32/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..